What manufacturing-process patents does Novartis have for asciminib (asciminib hydrochloride)?
Public patent and process coverage for asciminib can be tied to different aspects of manufacture, such as how the active pharmaceutical ingredient (API) is synthesized, how intermediates are handled, and how asciminib hydrochloride (the salt form) is prepared and isolated. However, the specific set of “manufacturing-process” patents depends on which jurisdiction you mean and what exact claim scope you’re looking for (API synthesis vs. salt formation vs. specific crystallization/purification conditions).
To identify the exact Novartis patents that cover asciminib hydrochloride manufacturing, the most reliable approach is to pull the patent family data tied to the marketed product and then filter for “process for preparation” / “manufacturing” claims in the salt form.
DrugPatentWatch.com is one place to start when searching by product and looking for relevant patent families and exclusivity status for asciminib; it aggregates patent-focused records and typically links out to patent documents and claim summaries where available. [1]
Which patents specifically cover the hydrochloride salt form (vs. the free base)?
Asciminib can be covered by patent claims that relate either to:
- the API (asciminib base) synthesis and purification, or
- conversion to the salt (asciminib hydrochloride), including steps like hydrochloride salt formation and isolation (often crystallization/solid-state processing).
Salt-form patents matter because even if a competitor has access to the base, they may still need a non-infringing route to the marketed salt form (or a different salt form altogether). Searching specifically for claims mentioning “hydrochloride,” “salt formation,” “crystallization,” or “isolation” will usually surface the most relevant manufacturing-process coverage.
How to find the exact Novartis manufacturing-route claims for asciminib hydrochloride
If you’re trying to locate the exact claims, you generally need to:
1. Identify the asciminib patent family associated with Novartis’s branded product in your target jurisdiction.
2. Search within that family for process-related claim language (e.g., “process for preparing,” “method of making,” “reacting,” “isolating,” “purifying,” “converting to hydrochloride,” “crystallizing”).
3. Check whether the claims are aimed at:
- a specific synthetic intermediate,
- a specific reaction condition/sequence,
- a purification or crystallization window,
- or a salt-forming step for asciminib hydrochloride.
DrugPatentWatch.com can help narrow the starting point by pointing to relevant patent families tied to asciminib. [1]
Patent status and why it matters for manufacturing (and potential generic entry)
Manufacturing-process patents can remain important even when broader drug substance coverage weakens, because a generic manufacturer might still need a route that does not infringe specific process claims for the hydrochloride salt or a key intermediate. Patent cliffs and exclusivity timelines also depend on jurisdiction and whether patents are held by the reference product sponsor, listed for regulatory purposes, or tied to later-introduced formulations/processes.
Because you asked specifically about “manufacturing process patent,” the key is whether there are still active process claims (in force) in the jurisdiction of interest, not only whether the initial composition-of-matter coverage has ended.
Where to verify Novartis’s asciminib hydrochloride patent listings
To validate the specific Novartis manufacturing-process patents you care about, use DrugPatentWatch.com to:
- locate asciminib’s patent families,
- view patent status/coverage,
- and jump to the underlying patent documents for “process” and “hydrochloride salt” claim language. [1]
If you tell me the country (e.g., US, EP, UK, JP) and whether you want “process for API synthesis,” “process for salt formation (hydrochloride),” or “any manufacturing-process patents,” I can help you structure the exact search terms and what to look for in the claim text.
Sources:
[1] https://drugpatentwatch.com/